SCHEMBL26567751

SCHEMBL26567751

Cc1ccc2sc(C3CC4(CC(NC(=O)C5CS(=O)(=O)C5)C4)C3)nc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.38
▸ ROCK2 O75116 1/20 0.36
▸ NPC1 O15118 5/20 0.35
▸ RAB9A P51151 5/20 0.35
▸ UBE2M P61081 3/20 0.35
▸ DCUN1D1 Q96GG9 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ TP53 P04637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ HDAC4 P56524 2/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.32
▸ GAA P10253 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ GLA P06280 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ RELA Q04206 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26567756 0.93 DYRK1A (0.36) DYRK1AROCK2NPC1RAB9AUBE2M
SCHEMBL26185604 0.88 NPC1 (0.43) ROCK2NPC1RAB9ALMNAMAPT
SCHEMBL29700519 0.88 NPC1 (0.43) ROCK2NPC1RAB9ALMNAMAPT
SCHEMBL26567770 0.86 DYRK1A (0.36) DYRK1ANPC1RAB9AUBE2MDCUN1D1
SCHEMBL26567808 0.82 DYRK1A (0.38) DYRK1AROCK2NPC1RAB9AUBE2M
SCHEMBL26567794 0.82 EPHX2 (0.38) DYRK1AROCK2NPC1RAB9AUBE2M
SCHEMBL29700425 0.81 NPC1 (0.43) ROCK2NPC1RAB9ALMNAMAPT
SCHEMBL26185602 0.81 NPC1 (0.43) ROCK2NPC1RAB9ALMNAMAPT
SCHEMBL26567790 0.80 ROCK2 (0.43) ROCK2LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL26567684 0.79 MAPK14 (0.38) DYRK1AROCK2UBE2MDCUN1D1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, NR1I3, NR1H4 DYRK1A 4673/4885ROCK2 3908/4885NPC1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback